Clinical and immunological significance of quantification of antibodies to type I, II, III collagen and elastin in systemic scleroderma

The aim of the work was to study clinical and immunological relevance of quantification of antibodies to type I, II, III collagen and elastin in systemic scleroderma. 51 systemic scleroderma patients with verified diagnosis and different disease activity were included in the study. 30 healthy volunteers were included in the control group. The laboratory markers were assessed both on admission and on discharge. 

Antibodies to serum type I, II, or III collagen, and elastin were measured using the ELISA test with antigen immobilized on the magnetic beads. Increased concentrations of antibodies to serum type I, II, or III collagen and elastin were found in systemic scleroderma with minimal disease activity. Statistical interrelations between antibody levels and disease activities and course types were also revealed. Skin, kidney, lung, and heart involvement in systemic scleroderma patients were associated with the more pronounced levels of antibodies to collagen compared to the absence of these conditions. 

Measurement of antibodies to serum type I, II, or III collagen and elastin in systemic scleroderma using antigen immobilized on magnetic beads is a candidate biomarker for better diagnosis and assessment of disease activity, course type, clinical pattern, treatment control, as well as useful tool for research of systemic scleroderma pathogenesis. 

1. Guseva N. G. Systemic scleroderma – a multidisciplinary problem. Nauchno-prakticheskaya revmatologiya [Scientific and practical rheumatology], 2011, vol. 49, no. 2, pp. 10–14 (in Russian).

2. Sigidin Ya. A., Guseva N. G., Ivanova M. M. Diffuse diseases of connective tissue. Moscow, Meditsina Publ., 2004. 640 p. (in Russian).

3. Potekaev N. N., Vavilov V. V. Pathogenesis of scleroderma: current ideas. Klinicheskaya dermatologiya i venerologiya [Clinical dermatology and venereology], 2012, vol. 10, no. 5, pp. 8–15 (in Russian).

4. Potekaev N. N., Korsunskaya I. M., Guseva S. D., Nevozinskaya Z. A. The role of autoantibodies in the development of scleroderma. Klinicheskaya dermatologiya i venerologiya [Clinical dermatology and venereology], 2014, vol. 12, no. 1, pp. 4–12 (in Russian).

5. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. Journal of Clinical Investigation, 2007, vol. 117, no. 3, pp. 557–567. https://doi.org/10.1172/JCI31139

6. Cipriani P., Marrelli A., Liakonli V., Di Benedetto P., Giacomelli R. Celluar players in angiogenesis during the course of systemic sclerosis. Autoimmunity Reviews, 2011, vol. 10, no. 10, pp. 641–647. https://doi.org/10.1016/j.autrev.2011.04.016

7. Gontar’ I. P., Rusanova O. A., Emel’yanova O. I., Krasil’nikov A. N. Correlation of the level of antibodies to elastin and elastase in patients with systemic scleroderma and systemic lupus erythematosus with pathology of the cardiovascular system. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of Volgograd State Medical University, 2019, no. 3, pp. 27–30 (in Russian).

8. Gontar’ I. P., Emel’yanova O. I., Rusanova O. A., Emel’yanov N. I., Krasil’nikov A. N., Zborovskaya I. A. The sequence of involvement of protein components of connective tissue in autoimmune inflammation in the scleroderma process. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education], 2019, no. 5, art. 114 (in Russian).

9. Chizzolini C., Brembilla N. C., Montanari E., Truchetet M.-E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmunity Reviews, 2011, vol. 10, pp. 276–281. https://doi.org/10.1016/j.autrev.2010.09.016

10. Robert L., Labat-Robert J. Les macromolecules de la matrice extracellulare. Annales de Biologie Clinique, 1986, vol. 44, no. 2, pp. 145–151.

11. Weijer C. Bioethics for clinicians: 10 Research ethics. CMAJ: Canadian Medical Association journal, 1997, vol. 156, no. 8, pp. 1153–1160.

12. Valentini G., Bencivelli W., Bombardieri S., D’Angelo S., Della Rossa A., Silman A. J., Black C. M., Czirjak L., Nielsen H., G. Vlachoyiannopoulos P. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Annals of the Rheumatic Diseases, 2003, vol. 62, no. 9, pp. 901–904. https://doi.org/10.1136/ard.62.9.901

13. Gontar’ I. P., Zborovskii A. B. Levkin S. V., Sycheva G. F. Method for producing magnetic polyacrylamide granules. Patent for the invention of the Russian Federation no. 1582657, 1993 (in Russian).